Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.71 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.67 |
| ▸ | PGK1 | P00558 | 1/20 | 0.64 |
| ▸ | PGK2 | P07205 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.61 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Nelarabine SCHEMBL31326718 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL1818971 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL9937290 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL14031852 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL18820 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL13575801 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL18321891 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL13657986 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL20769831 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B | |
| Nelarabine SCHEMBL29077509 | 1.00 | CYP2C19 (0.71) | CYP2C19ADORA2AADORA3ADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 692 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340868-A1 | POLYNUCLEOTIDES ENCODING LINKED ANTIGENS AND USES THEREOF | STEMCELL TECHNOLOGIES CANADA INC (CA) | 2025-11-06 | — | — | US | claimed |
| EP-4634380-A1 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-12357664-B2 | Optimized oncolytic viruses and uses thereof | SATOR THERAPEUTICS (US) | 2025-07-15 | — | — | US | claimed |
| WO-2025137275-A1 | NOVEL CAS NUCLEASES AND POLYNUCLEOTIDES ENCODING THE SAME | MODERNATX, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| EP-4565692-A2 | INTERNAL RIBOSOME ENTRY SITES FOR IMPROVED POLYNUCLEOTIDE TRANSLATION | ModernaTX, Inc. (US) | 2025-06-11 | — | — | EP | claimed |
| EP-4561602-A1 | POLYNUCLEOTIDES ENCODING LINKED ANTIGENS AND USES THEREOF | Stemcell Technologies Canada Inc. (CA) | 2025-06-04 | — | — | EP | claimed |
| CN-119866224-A | Polynucleotide encoding a linking antigen and uses thereof | 加拿大干细胞技术公司 | 2025-04-22 | — | — | CN | claimed |
| EP-4514328-A1 | LIPID NANOPARTICLES COMPRISING VENEZUELAN EQUINE ENCEPHALITIS (VEE) REPLICON AND USES THEREOF | Strand Therapeutics Inc. (US) | 2025-03-05 | — | — | EP | claimed |
| US-20250049950-A1 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | ARCTURUS THERAPEUTICS, INC. | 2025-02-13 | — | — | US | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| US-20190284260-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2019-09-19 | — | — | US | claimed |
| EP-3518947-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2019-08-07 | — | — | EP | claimed |
| WO-2018064134-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | Sator Therapeutics LLC (US) | 2018-04-05 | — | — | WO | claimed |
| US-20180085411-A1 | OPTIMIZED ONCOLYTIC VIRUSES AND USES THEREOF | SATOR THERAPEUTICS | 2018-03-29 | — | — | US | claimed |
| CN-102250178-A | Synthesis of nelarabine | JIANGSU CHIA TAI TIANQING PHAR | 2011-11-23 | — | — | CN | claimed |
| CN-101348511-A | Synthesis and refinement of nelarabine | JIANGSU CHIA TAI TIANQING PHAR (CN) | 2009-01-21 | — | — | CN | claimed |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | UNIVERSITY OF WASHINGTON (US) | 2005-08-25 | — | — | US | claimed |
| EP-0661291-B1 | Solid phase synthesis of oligoribonucleotide | AVENTIS PHARMA GMBH (DE) | 2001-03-07 | — | — | EP | claimed |
| US-5652358-A | Solid-phase synthesis of oligoribonucleotides | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-07-29 | — | — | US | claimed |
| EP-0661291-A1 | Solid phase synthesis of oligoribonucleotide | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-07-05 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049950-A1 | NUCLEIC ACIDS AND METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, RNMT, RNGTT | CYP2C19 4610/4885ADORA2A 1288/4885ADORA3 687/4885 |
| US-20050187180-A1 | Induction of viral mutation by incorporation of miscoding ribonucleoside analogs into viral RNA | SAMHD1, BCDIN3D, DCTD | CYP2C19 3339/4885ADORA2A 2027/4885ADORA3 1762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.